Characterization of antimicrobial resistance in gram-positive organisms identified in a fourth level of complexity ips in Barranquilla in 2013
Keywords:
Bacterial resistances, Microorganisms, AntimicrobialAbstract
The appearance of bacterial resistances with all the complications associated to its presence, it constitutes a problem of first line in public health on a global scale. The present study describes in a general form the resistance to antimicrobial in Gram-positive and Gram-negatives microorganisms identified in an IPS of 4 ° level of complexity of Barranquilla during the year 2013; this is why there was checked the information that fulfilled criteria of inclusion of descriptive and retrospective type of the epicentre of microbiology; where there was found 21 % (1.208) cases, predominating over bacilli Gram-negatives and Coccus Gram-positive, presenting more prevalence: Escherichia coli (E. coli) 16.88 %; Klebsiella pneumoniae, (Klebsiella p.) 11.92 %; Pseudomonas aeruginosa (P. aeruginosa) 9.02 %, Staphylococcus Aureus (S. Aureus) 8.70 %, Staphylococcus coagulase-negative (CoNS) 0.41 %. The most frequent infection identified in urine culture with 218 cases, followed by 171 cases in blood culture, 117 cases in soft tissues, finally with 68 cases in respiratory and 2 cases in culture of liquids; being the areas of major infection: Urgencies with 31.44 % (178) cases, followed by 8.65 % (49) cases in hospitalization, 8.48 % (48) cases in coronary ICU, later with 5.87 % (32) cases in pediatric ICU, 4.24 % (26) cases in neurological ICU and 4.4 % (25) cases in the area of 4th floor. The tax of phenotypical profile of resistance found is: In E. coli, they were presented 36.27 % (74) cases of resistance by extended spectrum beta-lactamase (ESBL) and 12.74 % by Carbapenemases (KPC); followed by Klebsiella p, with 36.80 % (53) cases of resistance by ESBL and 26.38 % (38) cases by KPC; S. aureus presented 54.23 % (57) cases of methicillin-resistant Staphylococcus aureus (MRSA) respectively. Being the universe of study all the samples of patients hospitalized due to infectious illnesses; from those antimicrobial used as the prescribed ones, a few of them presented sensibility of 90-100 %, a reason why they could be suggested as an option for treatment of the infections caused by Gram-positives and Gram-negatives agents. It is required to optimize and extend the effectiveness of the antimicrobial available agents and follow the restriction of their uses and the prescription approved by the committee of infections in accordance with the parameters stipulated by the WHO.
Downloads
References
2. Becerra G, Plascencia A, Lluévanos A, Domínguez M, Hernández I. Mecanismo de resistencia a antimicrobianos en bacterias. Enf Microbiol. [serie de Internet]. 2009 [citado 2014 ene 18]; 29 (2). Disponible: http:// www.amimc.org.mx/revista/2009/29-2/mecanismo. pdf
3. De Kraker ME, Davey PG, Grundmann H, BURDEN study group. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med [serie de Internet]. 2011 [citado 2014 feb 15]; 8(10). Disponible:http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3191157/?tool=pubm
4. De Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother. 2011; 66(2): 398-407.
5. World Health Organization. [homepage on the Internet]. Resistencia a los antimicrobianos (RAM); 2011 [updated 2013 dic 18; cited 2014 abr 2]. Disponible en: http://www.who. int/mediacentre/factsheets/fs194/es/index. html
6. Pérez A, Dennis RJ, Rodríguez B, Castro AY, Delgado V, Lozano JM, Castro MC. An interrupted time series analysis of parenteral antibiotic use in Colombia. J Clin Epidemial. 2003; 56(10): 1013-1020.
7. Leal AL, Buitrago G, Álvarez C. Vigilancia de resistencia bacteriana. Resultados. Primer trimestre de 2005. Boletín Epidemiológico Distrital. Secretaría Distrital de Salud de Bogotá. 2005; 10(7).
8. Sistema automatizado para microbiología: BD PHOENIX. Disponible en: http://www. sochinf.cl/sitio/templates/sochinf2008/documentos/ presentaciones_microbiologia_ cli_2010/03_14_00_Prat.pdf
9. Tillán Ochoa G. Actualidad y tendencias en el mercado del diagnóstico in vitro. Revista CENIC. 2005; (36).
10. Fagundo-Sierra R, et al. Evaluación del equipo automatizado Phoenix para la detección de β-lactamasas de espectro extendido en aislamientos clínicos de Escherichia coli y Klebsiella pneumoniae. Artículo original Microbiología. México, D.F.; 2008.
11. Martínez-Lamas L, Treviño Castellano M, Romero- Jung PA, Regueiro García et BJ. Comparación entre el sistema Phoenix y métodos basados en agar para el ensayo de sensibilidad a antibióticos en Streptococcus spp. Rev. Esp Quimioter 2008; 21(3): 184-8.
12. Villegas MV, Lolans K, Del Rosario Olivera M, Suarez CJ. First detection of metalloid-betalactamase VIM-2 in Pseudomonas aeruginosa isolates from Colombia. Antimicrobial Agents Chemother 2006; 50: 226-9. 13. Grupo para el control de la resistencia bacteriana. Boletín Informativo GREBO. Bogotá; 2009.
14. Ministerio de la Protección Social. Indicador Tasa de Infección Intrahospitalaria (I.3.2), Comportamiento según departamentos. [homepage on the Internet]; 2009. [actualizado 2013 dic 20; citado 2014 ene 16]. Disponible en: http://www.minproteccionsocial.gov.co/ VBeContent/Library/documents/DocNews- No16130DocumentNo4144.pdf
15. Villegas MV, Lolans K, Correa A, Kattan JN, López JA, Quinn JP. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenems-hydrolyzing betalactamase. Antimicrobial Agents Chemother 2007; 51: 1553-5.
16. Gonzalez-Mejia EB, Valenzuela EM, Mantilla- Anaya JR. Resistance to cefepima in Enterobacter cloacae isolates from hospitals in Bogota, Colombia. Rev Salud Pública (Bogotá) 2006; 8: 191-9.
17. Bantar C, Curcio D, Fernandez Canigia L, Garcia P, Guzman Blanco M, Leal AL. Comparative in vitro activity of tigeciclina against bacteria recovered from clinical specimens in Latin America. J Chemother 2009; 21: 144- 52.
18. Cortés JA, Alvarez CA, Leal Al, Grebo. Antimicrobial resistance in big hospitals in Bogota, Colombia, 2001-2003. Clin Microbial Infect. 2004; 10(S3): 1-86.
19. Espinosa C, Castillo JS, Cortés JA, Leal AL. Cuál es el perfil de resistencia de Cocos Gram positivos aislados en los hospitales en Colombia, 2001-2007. Act Med Colombia 2008; 33: 1-5.
